Detalles de la búsqueda
1.
Protocol for the nationwide registry of patients with polycystic kidney disease: japanese national registry of PKD (JRP).
Clin Exp Nephrol
; 2024 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38734869
2.
Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy.
Int J Mol Sci
; 25(4)2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38396765
3.
Impact of cisplatin-induced acute kidney injury on long-term renal function in patients with solid tumors.
Clin Exp Nephrol
; 27(6): 506-518, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36941500
4.
Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 27(10): 809-818, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37368094
5.
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Int J Clin Oncol
; 28(10): 1259-1297, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382749
6.
Prediction of recovery time of urinary incontinence following robot-assisted laparoscopic prostatectomy.
Int J Urol
; 30(1): 77-82, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36305653
7.
Predicting perioperative outcomes of robot-assisted radical cystectomy: Data from the Asian Robot-Assisted Radical Cystectomy Consortium.
Int J Urol
; 29(9): 1002-1009, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35613922
8.
Perioperative Outcomes of Robot-Assisted Radical Cystectomy with Intracorporeal Versus Extracorporeal Urinary Diversion.
Ann Surg Oncol
; 28(13): 9209-9215, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34152523
9.
Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
Clin Exp Nephrol
; 25(11): 1231-1239, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34228250
10.
Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
Clin Exp Nephrol
; 25(9): 1003-1010, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34089122
11.
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 25(5): 467-478, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33471240
12.
Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Clin Exp Nephrol
; 25(9): 970-980, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33928479
13.
Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Am J Nephrol
; 51(11): 881-890, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33227802
14.
The relationship between liver cyst volume and QOL in Japanese ADPKD patients.
Clin Exp Nephrol
; 24(4): 314-322, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31875934
15.
Surveillance after prostate focal therapy.
World J Urol
; 37(3): 397-407, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29948045
16.
Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Clin Exp Nephrol
; 28(2): 123-124, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38070021
17.
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Clin Exp Nephrol
; 28(2): 85-122, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878114
18.
Correction to: Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 28(1): 82-83, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37924433
19.
Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.
Cancer Sci
; 109(4): 1230-1238, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29369461
20.
Novel semi-automated kidney volume measurements in autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 22(3): 583-590, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29101551